I'm LongbridgeAI, I can summarize articles.Eli Lilly (LLY) fell 3.43% this week to close at $1,142.85, underperforming the S&P 500 by about 3.16 percentage points. The stock opened near $1,180 and initially held that range through Monday and Tuesday. On Wednesday it touched an intraday high of $1,215 before reversing lower, with volume expanding to roughly 3.4m shares. Thursday and Friday extended the pullback, with the week’s low at $1,136.66. Weekly amplitude was 6.64%, and turnover came to about $13.
The Week
Eli Lilly (LLY) fell 3.43% this week to close at $1,142.85, underperforming the S&P 500 by about 3.16 percentage points. The stock opened near $1,180 and initially held that range through Monday and Tuesday. On Wednesday it touched an intraday high of $1,215 before reversing lower, with volume expanding to roughly 3.4m shares. Thursday and Friday extended the pullback, with the week’s low at $1,136.66. Weekly amplitude was 6.64%, and turnover came to about $13.2bn, with average daily volume running about 5.7% below the 60-day median.
Key Events
The week was dominated by Lilly’s obesity and diabetes pipeline. From Wednesday, the company disclosed several datasets. Foundayo (orforglipron), its oral GLP-1, showed cardiovascular safety in its largest and longest type 2 diabetes study; a post-hoc analysis tied 17.2 mg to a 57% reduction in predicted 10-year diabetes risk and an 18% reduction in cardiovascular risk versus placebo. EloraTZP, a combination of eloralintide and tirzepatide, delivered greater weight loss and A1C reduction than tirzepatide 15 mg in a mid-stage trial, and Lilly plans to begin Phase 3 studies by end-2026. Elsewhere, EBGLYSS showed benefits in moderate-to-severe hand and foot atopic dermatitis, and Jaypirca received an expanded FDA indication for previously untreated CLL/SLL. The market’s weighing of EloraTZP’s efficacy against tolerability concerns formed the backdrop for Friday’s decline.
Analyst Ratings
32 institutions cover Lilly: 19 rate it buy, 6 over, 3 hold, 1 under, 1 sell, and 2 have no opinion. The consensus rating is buy, with a consensus target price of $1,328.83, about 16.3% above the latest price. Targets range from $930 to $1,600, a wide spread. Within the pharmaceutical industry of 203 names, Lilly ranks first by analyst rating.
The Week Ahead
The macro calendar is busy next week: S&P Global services PMI and ISM services PMI on Monday, trade balance data on Tuesday, and EIA crude inventory figures on Wednesday. On the company side, Lilly’s Q3 FY2026 earnings are scheduled for 29 October, with consensus estimates around $9.25 EPS and $22.4bn revenue. The obesity pipeline data released this week may remain in focus as investors digest tolerability details.
In Short
The ratings picture remains favourable: consensus is buy, Lilly ranks first in its industry, and the consensus target sits above spot. Yet the stock fell 3.43% this week after peaking mid-week, as EloraTZP’s efficacy was weighed against tolerability concerns. Valuation adds another layer of tension, with a static P/E near 40x and P/B around 31.8x. The latest session’s flow shows divergence between large and small orders. The next test is whether tolerability data get clarified, and how next week’s macro prints move rate-sensitive pharma.\n\nThis article is generated by LongbridgeAI from market data, for information only and not investment advice.